GB202104388D0 - Methotrexate pharmaceutical composition - Google Patents

Methotrexate pharmaceutical composition

Info

Publication number
GB202104388D0
GB202104388D0 GBGB2104388.0A GB202104388A GB202104388D0 GB 202104388 D0 GB202104388 D0 GB 202104388D0 GB 202104388 A GB202104388 A GB 202104388A GB 202104388 D0 GB202104388 D0 GB 202104388D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical composition
methotrexate
methotrexate pharmaceutical
composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB2104388.0A
Other versions
GB2591681A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FTF Pharma Pvt Ltd
Original Assignee
FTF Pharma Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FTF Pharma Pvt Ltd filed Critical FTF Pharma Pvt Ltd
Publication of GB202104388D0 publication Critical patent/GB202104388D0/en
Publication of GB2591681A publication Critical patent/GB2591681A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB2104388.0A 2018-08-29 2019-08-29 Methotrexate pharmaceutical composition Withdrawn GB2591681A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201821032299 2018-08-29
PCT/IB2019/000949 WO2020044114A2 (en) 2018-08-29 2019-08-29 Methotrexate pharmaceutical composition

Publications (2)

Publication Number Publication Date
GB202104388D0 true GB202104388D0 (en) 2021-05-12
GB2591681A GB2591681A (en) 2021-08-04

Family

ID=68582041

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2104388.0A Withdrawn GB2591681A (en) 2018-08-29 2019-08-29 Methotrexate pharmaceutical composition

Country Status (2)

Country Link
GB (1) GB2591681A (en)
WO (1) WO2020044114A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115778897A (en) * 2022-12-15 2023-03-14 深圳市贝美药业有限公司 Stable methotrexate pharmaceutical preparation and preparation method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5925669A (en) 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
US5770585A (en) 1995-05-08 1998-06-23 Kaufman; Robert J. Homogeneous water-in-perfluorochemical stable liquid dispersion for administration of a drug to the lung of an animal
SE9502244D0 (en) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
DE102006033837A1 (en) * 2006-07-21 2008-01-31 Medac Gesellschaft für klinische Spezialpräparate m.b.H Concentrated methotrexate solutions
GB201200192D0 (en) 2012-01-06 2012-02-22 Rosemont Pharmaceuticals Ltd Methotrexate composition
GB201419261D0 (en) * 2014-10-29 2014-12-10 Therakind Ltd Formulations

Also Published As

Publication number Publication date
WO2020044114A3 (en) 2020-04-09
GB2591681A (en) 2021-08-04
WO2020044114A2 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
IL271657A (en) Pharmaceutical compositions
IL271986B1 (en) Pharmaceutical composition
GB201712159D0 (en) Pharmaceutical composition
GB201804548D0 (en) Pharmaceutical compositions
GB201705303D0 (en) Pharmaceutical compositions
SG11202001179YA (en) Pharmaceutical compositions
GB201911517D0 (en) Pharmaceutical composition
GB201719447D0 (en) Pharmaceutical composition
IL272419A (en) Pharmaceutical composition
GB201705305D0 (en) Pharmaceutical compositions
GB201807053D0 (en) Pharmaceutical composition
GB201705306D0 (en) Pharmaceutical compositions
GB201705304D0 (en) Pharmaceutical compositions
SG11202103374TA (en) Pharmaceutical composition
EP3727485C0 (en) Pharmaceutical composition
GB201808571D0 (en) Pharmaceutical compositions
GB202104388D0 (en) Methotrexate pharmaceutical composition
SG11202110315SA (en) Pharmaceutical composition
FI3908321T3 (en) Pharmaceutical composition
IL272044A (en) Pharmaceutical compositions
GB201808567D0 (en) Pharmaceutical compositions
GB201820689D0 (en) Pharmaceutical composition
ZA202006541B (en) Pharmaceutical composition comprising brexpiprazole
IL285728A (en) Pharmaceutical composition
EP4066852A4 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)